Sai Life Sciences Ltd management interview: A Strong Q2 For Sai Life Sciences | See A Lot More Intent From Pharma Cos To De-Risk From China: Co
CNBC-TV18, 2026-11-11. Video: https://www.youtube.com/watch?v=N7qViX4pxng
- Growth targets: Sai Life Sciences does not provide annual revenue or profitability guidance, but reiterated long-term guidance of 15-20% CAGR in revenue and 28 to 30% EBITDA.
- CRO and CDMO: Management sees China-related tailwinds and broader growth opportunities for Indian CRDMOs. Sai’s ability to operate both CRO and CDMO businesses at scale supports integrated strategic partnerships with pharma customers.
- Peptide expansion: Sai is pursuing peptides outside the GLP-1 space, including macrocyclic peptides, and is developing discovery, process-development and manufacturing capabilities.
- Formulation plans: The initial focus is clinical formulations for preclinical, phase 1 and early phase 2 work, not commercial formulations. Work has started, and Sai expects to build on relationships with 19 out of the 25 large pharma companies it works with.
- China+1 outlook: Management says uncertainty around China remains a reason for pharma companies to diversify, and reports more visits, information requests and partnership discussions. It could not quantify how much of Sai’s business comes from China+1, but said the company had beaten analyst expectations for 8 quarters.